VIPR2 and COVID-19: Together, our results indicate that subset of tuft cells exhibit notable associations with severe COVID‐19, and critical drug targets, including IL10RB, ICAM1, and VIPR2, are prioritized for treating severe COVID‐19 and concomitant intestinal symptoms.